A Randomised, Double-Blind, Placebo-Controlled Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HDM1005 Injection Administered as a Single Subcutaneous Injection in Increasing Doses in Healthy Subjects
Latest Information Update: 22 Oct 2024
Price :
$35 *
At a glance
- Drugs HDM 1005 (Primary)
- Indications Obesity; Overweight; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
- 22 Oct 2024 New trial record